Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies

Shoreline Biosciences, Inc. and BeiGene, Ltd. announced a worldwide collaboration to develop and commercialize a portfolio of natural killer (NK)-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies.